MERCER COUNTY REGIONAL PLANNING COMMISSION
MCRPC's services include, but are not limited to, the preparation of comprehensive plans, zoning ordinances, subdivision administration and ordinances, recreation planning, community facility planning, environmental assessments, grant writing and administration for a variety of programs including SCPAP, communities of opportunities, community revitalization program, CDBG, pennvest, keystone recreation, HOME, etc.
MERCER COUNTY REGIONAL PLANNING COMMISSION
Social Links:
Industry:
Communities Government Non Profit Recreation Smart Cities
Founded:
1952-01-01
Address:
Hermitage, Pennsylvania, United States
Country:
United States
Website Url:
http://www.mcrpc.com
Total Employee:
1+
Status:
Active
Contact:
+1 724 981 2412
Email Addresses:
[email protected]
Official Site Inspections
http://www.mcrpc.com Semrush global rank: 2.9 M Semrush visits lastest month: 5.61 K
- Host name: cloudproxy10130.sucuri.net
- IP address: 192.124.249.130
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Mercer County Regional Planning Commission"
Metastatic Castration-Resistant Prostate Cancer: Advances in
Jun 24, 2024 · Herein, we discuss the most recent advancements in mCRPC treatment, the mechanisms of action, the nuances of trials, and the direction in which this field is heading. We …See details»
Advances in mCRPC Management: Recent Approvals, Emerging …
Nov 15, 2024 · Prostate cancer is the second leading cancer and the most common cause of cancer-related mortality in men, resulting in approximately 397,000 deaths globally in 2022. 1 …See details»
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
With Metastatic Castration-Resistant Prostate Cancer (mCRPC), hormone therapy no longer stops cancer growth. Cancer is found in other tissues and organs. The main goal for treating …See details»
mCRPC Treatment - UroToday
BACKGROUND - Treatment of metastatic castration-resistant prostate cancer (mCRPC) with chemotherapy improves disease control and survival in fit older men (age 65+) but its impact …See details»
Consensus on the Treatment and Follow-Up for …
Generate a consensus on critical issues relevant to treatment of metastatic castration-resistant prostate cancer (PCa) focused in developing countries. Knowledge Generated. Consensus was reached for metastatic castration …See details»
Real-world treatment patterns and overall survival among men …
Oct 2, 2023 · Real-world treatment patterns and survival in metastatic castration-resistant prostate cancer (mCRPC) have not been characterized for the full fee-for-service Medicare population. …See details»
Therapeutic sequencing improves outcomes for patients with …
Nov 20, 2020 · In the modern era, several promising treatment options have emerged for the management of mCRPC, including androgen receptor inhibitors (ARIs) such as abiraterone …See details»
Real-world management of metastatic castration-resistant …
Feb 16, 2022 · Conclusions: In this real-world analysis of mCRPC patients, ARAT therapy was the preferred approach for first-line treatment intensification in over 108 (80%) patients. Despite …See details»
Current and Emerging Therapies for Metastatic Castration …
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and …See details»
Lynparza® (olaparib) Receives Health Canada Approval for
MISSISSAUGA, ON, NOV 25, 2020 – On August 21, 2020, Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious …See details»
Therapeutic implications of homologous repair deficiency testing …
Sep 27, 2024 · Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize …See details»
mCRPC Treatment: The Right Treatment for the Right Patient
Feb 13, 2017 · In patients with mCRPC with low disease burden and few symptoms—or patients with slow-moving disease without visceral metastases and a fairly good prognosis—it’s …See details»
Treatment patterns and outcomes for metastatic castration …
Feb 26, 2019 · Background: In the era of expanding therapeutic options for mCRPC, there is a growing need to develop an optimal treatment sequence. This real-world study evaluated …See details»
WHAT YOU SHOULD KNOW ABOUT mCRPC Metastatic Castration …
TREATMENT OPTIONS FOR mCRPC The main goal for treating mCRPC is to control symptoms and slow progress. Even though androgen deprivation therapy (ADT) or hormone therapy may …See details»
What Is Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
Nov 12, 2024 · Metastatic castration-resistant prostate cancer (mCRPC) and its precursor, metastatic hormone sensitive prostate cancer (mHSPC), are advanced forms of the condition …See details»
mCRPC - What You Should Know - Urology Care Foundation
Metastatic Castration-Resistant Prostate Cancer (mCRPC) - What You Should Know Fact Sheet A concise summary of Metastatic Castration –Resistant Prostate Cancer to help patients …See details»
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Apr 28, 2020 · We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease …See details»
The Current State of Treatment Implementation for mCRPC in
In this Center of Excellence article, we will discuss the current state of treatment utilization for mCRPC patients in North America and provide a contemporary approach to the management …See details»
Metastatic Castration-Resistant Prostate Cancer Previously Treated …
Sep 27, 2018 · PROXIMA is a prospective, observational study designed to examine real-world treatment patterns of patients with mCRPC whose disease progressed during or after a …See details»
Abiraterone and Olaparib for Metastatic Castration-Resistant …
Jun 3, 2022 · We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting. Patients were enrolled …See details»